Transplant Conditioning with Mobilization Only 비교

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 2 Transplant Conditioning with Mobilization Only (Transplant Conditioning with Mobilization Only) Millennium Pharmaceuticals, Inc.·Severe Combined Immunodeficiency 30 trials

Overview Program	Transplant Conditioning with Mobilization Only
Overview Company	Millennium Pharmaceuticals, Inc.
Overview Modality	CGT
Overview Target	Severe Combined Immunodeficiency
Overview Indication	Severe Combined Immunodeficiency
Overview Phase	PHASE_2
Overview Status	DISCONTINUED
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

Toxicology Major finding	interstitial lung disease (iILD) versus 1000mg/m 2 otherwise, both reduced compared to the ASTIS
Toxicology CRS	70%

Clinical Safety signal	interstitial lung disease (iILD) versus 1000mg/m 2 otherwise, both reduced compared to the ASTIS
Clinical Result source	ClinicalTrials.gov NCT01045460
Clinical Program phase	PHASE_2
Clinical Trial ref	NCT01045460

선택됨 (1/5)

추천 · 인기 프로그램

최대 5개 선택 · 전체 25+ 프로그램은 검색으로 찾을 수 있습니다. ADC 목록 →

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 2 Transplant Conditioning with Mobilization Only (Transplant Conditioning with Mobilization Only) Millennium Pharmaceuticals, Inc.·Severe Combined Immunodeficiency 30 trials

Overview Program	Transplant Conditioning with Mobilization Only
Overview Company	Millennium Pharmaceuticals, Inc.
Overview Modality	CGT
Overview Target	Severe Combined Immunodeficiency
Overview Indication	Severe Combined Immunodeficiency
Overview Phase	PHASE_2
Overview Status	DISCONTINUED
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

Toxicology Major finding	interstitial lung disease (iILD) versus 1000mg/m 2 otherwise, both reduced compared to the ASTIS
Toxicology CRS	70%

Clinical Safety signal	interstitial lung disease (iILD) versus 1000mg/m 2 otherwise, both reduced compared to the ASTIS
Clinical Result source	ClinicalTrials.gov NCT01045460
Clinical Program phase	PHASE_2
Clinical Trial ref	NCT01045460